Trial Radar

Trial testing INCB000928 alone or with ruxolitinib to treat anemia in myelofibrosis patients, assessing safety and effectiveness.

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the…

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in…

New drug BIA 28-6156 tested against placebo to slow motor decline in GBA gene-linked Parkinson's disease over 78 weeks.

An experimental drug tested to see if it slows tau protein buildup in early Alzheimer's disease using brain scanning.

A new drug combined with tirzepatide tested against tirzepatide alone for weight loss in overweight or obese adults over 48 weeks.

A 35-week trial testing whether brenipatide injections improve symptoms and are safe in patients with IBS-diarrhea compared to placebo.

What is being tested: Rapcabtagene autoleucel, a CAR-T cell therapy administered as a single infusion after lymphodepletion, compared against rituximab in patients with severe,…

What is being tested: KPL-387 monotherapy dosing regimens designed to safely transition patients from established pericarditis treatments, evaluating efficacy and safety profiles during this…

What is being tested: Trastuzumab deruxtecan (T-DXd), a HER2-targeted antibody-drug conjugate, administered alone or combined with chemotherapy and/or immunotherapy in patients with HER2-expressing advanced…

What is being tested: SAB-142, a human anti-thymocyte immunoglobulin, is being evaluated to determine whether it can arrest the progression of Type 1 Diabetes…

What is being tested: Sparsentan (a dual endothelin receptor antagonist and angiotensin II receptor blocker) administered as oral suspension or tablets in once-daily dosing…

Treatment being tested: Raludotatug deruxtecan (R-DXd), a novel targeted therapy designed to treat platinum-resistant high-grade ovarian, primary peritoneal, and fallopian tube cancers by combining…

TIN816 drug tested at three doses in critically ill patients with kidney injury from sepsis to assess safety and effectiveness.

Guselkumab, a new antibody treatment, shows promise for reducing symptoms and inflammation in moderate-to-severe Crohn's disease.

Long-term safety follow-up study of a gene therapy injection into the eye for geographic atrophy, a type of age-related macular degeneration.

Guselkumab was tested for treating moderate to severe ulcerative colitis, assessing whether it works and is safe.

Drug being tested: BMS-986435/MYK-224, a novel therapeutic agent being evaluated for safety, tolerability, and pharmacokinetic exposure in patients with symptomatic HFpEF. Patient eligibility: The…

Drug being tested: Icotrokinra, a novel therapeutic agent, is being evaluated for its efficacy and safety profile in treating moderately to severely active Crohn's…

New antibody treatment tested to prevent lung flare-ups in bronchiectasis patients with chronic bacterial infection.

Trial testing safety and early effectiveness of BMS-986507 combined with other drugs in adults with advanced cancer.

Study testing whether radioactive iodine treatment is needed after surgery for low-risk thyroid cancer patients.

Testing combination immunotherapy and targeted drugs in newly diagnosed advanced kidney cancer to assess safety and effectiveness.

Testing combined immunotherapy and targeted drugs in patients with advanced kidney cancer who've had previous treatments.

What is being tested: Surovatamig, a novel subcutaneous therapeutic agent, is being evaluated for its safety, tolerability, pharmacokinetics, and efficacy in treating primary membranous…

What is being tested: Three different GvHD prophylaxis strategies following unrelated donor stem cell transplantation: Thymoglobulin, calcineurin inhibitor-based regimens, and sirolimus-based post-transplant cyclophosphamide approaches.…

What is being tested: The optimal duration of platinum-based chemotherapy (3 vs 6 cycles) prior to maintenance avelumab immunotherapy in patients with advanced urothelial…

AZD1163 was tested in moderate-to-severe rheumatoid arthritis patients to assess whether it works and is safe.

SAT-3247 tested at two doses versus placebo in children aged 7-10 with muscular dystrophy over 12 weeks to find the best dose and safety…

A new blood cancer drug (acalabrutinib) is being tested for safety and effectiveness in treating chronic lymphocytic leukaemia.

ALL-RIC Trial Summary Trial comparing two pre-transplant chemotherapy regimens in older adults with acute lymphoblastic leukaemia to reduce disease relapse without increasing transplant mortality.

What is being tested: Next generation Stereotactic Ablative Radiotherapy (SABR) with integrated toxicity reduction strategies for low, intermediate, and eligible high-risk prostate cancer, evaluated…

What is being tested: Disitamab vedotin, a novel antibody-drug conjugate, is being evaluated in combination with other anticancer agents to determine efficacy and safety…

What is being tested: AZD4144, an investigational drug being evaluated for its efficacy, safety, and tolerability in treating sepsis-associated acute kidney injury (AKI), a…

What is being tested: RLY-2608, a mutant-selective PI3Kα inhibitor, is being evaluated for safety and efficacy in treating PIK3CA-related overgrowth spectrum (PROS) and PIK3CA-driven…

Treatment being tested: PF-07275315, an investigational medicine for moderate-to-severe asthma, with assessment of its safety profile and clinical efficacy in reducing breathing difficulties. Patient…

RP-A501 is a gene therapy using AAV9 vector to deliver the LAMP2B gene – designed to address the underlying genetic defect in Danon disease…

What is being tested: Safety and tolerability of difelikefalin, a novel therapeutic agent, in adolescent patients undergoing haemodialysis who experience moderate-to-severe pruritus (a significant…

Treatment being tested: ALG-000184, a novel oral antiviral agent administered once daily as monotherapy, compared against the established standard tenofovir disoproxil fumarate (TDF) in…

What is being tested: This trial evaluates whether coronary artery stent placement improves outcomes in patients with HFpEF who have concurrent coronary artery disease,…

Drug and target: Lirafugratinib, a selective FGFR2 inhibitor, is being tested in previously treated patients with advanced/metastatic solid tumours (excluding cholangiocarcinoma) that harbour FGFR2…

What is being tested: ASP5541, a novel androgen receptor pathway inhibitor (ARPI), is being evaluated in a Phase 2 study as a potential treatment…

A study testing a new antibody drug to block myostatin in adults with facioscapulohumeral muscular dystrophy.

Alpelisib (a targeted drug) tested in children and adults with PIK3CA gene mutations causing abnormal tissue overgrowth.

Three immunotherapy combinations tested in chemotherapy-ineligible patients with advanced bladder cancer: LAG-3 alone, LAG-3 plus TIGIT inhibitor, versus PD-L1 inhibitor.

Intervention being tested: Faecal Microbiota Transplant (FMT) versus placebo in patients with primary sclerosing cholangitis (PSC), a rare autoimmune liver disease with no established…

What is being tested: Long-term safety and efficacy outcomes of Avalyn's inhaled antifibrotic agent (AP01) in participants who previously completed earlier phase trials, using…

This trial tests whether a new medicine (PGN-EDODM1) is safe and works for people with myotonic dystrophy type 1.

This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the…

Adagrasib showed benefit in elderly or unfit lung cancer patients with KRASG12C mutations who couldn't tolerate standard treatments.